Sun Pharma ranks second in US dermatology by prescriptions, with key brands including Ilumya for plaque psoriasis and Winlevi for acne. Rec...

Brazilian Foreign Minister Mauro Vieira has described Brazil, South Africa and India as major democratic partners of the Global South, stre...

Invesco India has unveiled an innovative pharma and healthcare fund tailored for investors seeking opportunities in India's burgeoning heal...

US tariff threats on Indian generic drugs face significant obstacles. These duties could increase American healthcare costs and potentially...

Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two stren...

After undergoing a heart transplant, a survivor encountered steep increases in medication costs, initially losing her insurance coverage on...

Independence Day 2026: From the Swadeshi movement to Atmanirbhar Bharat. Early Swadeshi movements fostered indigenous industries against im...

2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...

Dr Reddy's Laboratories has launched its generic Sugammadex injection in the United States. This new product reverses muscle relaxant effec...

The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...

US pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...

The Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair...

US President Donald Trump threatened steep tariffs on generic drugmakers. He stated medicines must be manufactured locally or face signific...

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...

President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...

For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...